Proteomic data derived from Immunovia’s IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases
- Thursday, January 7, 2021, 7:03
- Finance
- Add a comment
LUND, Sweden, Jan. 7, 2021 /PRNewswire/ — Immunovia AB, (“Immunovia”) a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced results from a study in their development pipeline, published in the…
About the Author
adminasapcorp has written 41552 stories on this site.